Public offering nets $380mm for bluebird bio

15:40 EDT 29 Jun 2017 | Elsevier Business Intelligence

Gene editing and immunotherapy firm bluebird bio Inc. netted $380mm through the public sale of 3.8mm common shares at $105. P...

Original Article: Public offering nets $380mm for bluebird bio


More From BioPortfolio on "Public offering nets $380mm for bluebird bio"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...